Paediatric European Network for Treatment of AIDS (PENTA) Guidelines for Treatment of Paediatric HIV-1 Infection 2015: Optimizing Health in Preparation for Adult Life

Overview

Journal HIV Med

Publisher Wiley

Specialty Infectious Diseases

Date 2015 Feb 5

PMID 25649230

Citations 50

Authors

A Bamford

A Turkova

H Lyall

C Foster

N Klein

D Bastiaans

D Burger

S Bernadi

K Butler

E Chiappini

P Clayden

M Della Negra

V Giacomet

C Giaquinto

D Gibb

L Galli

M Hainaut

M Koros

L Marques

E Nastouli

T Niehues

A Noguera-Julian

P Rojo

C Rudin

H J Scherpbier

G Tudor-Williams

S B Welch

Affiliations

Soon will be listed here.

Abstract

The 2015 Paediatric European Network for Treatment of AIDS (PENTA) guidelines provide practical recommendations on the management of HIV-1 infection in children in Europe and are an update to those published in 2009. Aims of treatment have progressed significantly over the last decade, moving far beyond limitation of short-term morbidity and mortality to optimizing health status for adult life and minimizing the impact of chronic HIV infection on immune system development and health in general. Additionally, there is a greater need for increased awareness and minimization of long-term drug toxicity. The main updates to the previous guidelines include: an increase in the number of indications for antiretroviral therapy (ART) at all ages (higher CD4 thresholds for consideration of ART initiation and additional clinical indications), revised guidance on first- and second-line ART recommendations, including more recently available drug classes, expanded guidance on management of coinfections (including tuberculosis, hepatitis B and hepatitis C) and additional emphasis on the needs of adolescents as they approach transition to adult services. There is a new section on the current ART 'pipeline' of drug development, a comprehensive summary table of currently recommended ART with dosing recommendations. Differences between PENTA and current US and World Health Organization guidelines are highlighted and explained.

Citing Articles

Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV.

Tsirizani L, Mohsenian Naghani S, Waalewijn H, Szubert A, Mulenga V, Chabala C J Antimicrob Chemother. 2024; 79(11):2990-2998.

PMID: 39302766 PMC: 11531812. DOI: 10.1093/jac/dkae319.

Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV - Week 48....

Compagnucci A, Chan M, Saidi Y, Cressey T, Bamford A, Riault Y EClinicalMedicine. 2023; 60:102025.

PMID: 37304494 PMC: 10251070. DOI: 10.1016/j.eclinm.2023.102025.

Adoption is not associated with immunological and virological outcomes in children with perinatally acquired HIV infection in the Netherlands.

van den Hof M, Smit C, van Rossum A, Fraaij P, Wolfs T, Geelen S PLoS One. 2023; 18(5):e0284395.

PMID: 37141310 PMC: 10159147. DOI: 10.1371/journal.pone.0284395.

Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial.

Ajibola G, Maswabi K, Hughes M, Bennett K, Pretorius-Holme M, Capparelli E J Acquir Immune Defic Syndr. 2023; 92(5):393-398.

PMID: 36729692 PMC: 10006291. DOI: 10.1097/QAI.0000000000003147.

Drug resistance in children and adolescents with HIV in Panama.

Ventosa-Cubillo J, Pinzon R, Gonzalez-Alba J, Estripeaut D, Navarro M, Holguin A J Antimicrob Chemother. 2022; 78(2):423-435.

PMID: 36454248 PMC: 9890268. DOI: 10.1093/jac/dkac407.

References

Purdy J, Gafni R, Reynolds J, Zeichner S, Hazra R . Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr. 2008; 152(4):582-4. PMC: 2390888. DOI: 10.1016/j.jpeds.2007.12.020. View

Green H, Gibb D, Walker A, Pillay D, Butler K, Candeias F . Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS. 2007; 21(8):947-55. DOI: 10.1097/QAD.0b013e3280e087e7. View

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S . Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS. 2008; 22(17):2279-89. PMC: 2745911. DOI: 10.1097/QAD.0b013e328311d16f. View

. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS. 2006; 20(10):1391-9. DOI: 10.1097/01.aids.0000233572.59522.45. View

Urschel S, Ramos J, Mellado M, Giaquinto C, Verweel G, Schuster T . Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected children under highly active antiretroviral therapy. AIDS. 2005; 19(18):2103-8. DOI: 10.1097/01.aids.0000194795.20928.2b. View

Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D . Short-course antiretroviral therapy in primary HIV infection. N Engl J Med. 2013; 368(3):207-17. PMC: 4131004. DOI: 10.1056/NEJMoa1110039. View

Zampoli M, Kilborn T, Eley B . Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children. Int J Tuberc Lung Dis. 2007; 11(4):417-23. View

Wirth S, Ribes-Koninckx C, Calzado M, Bortolotti F, Zancan L, Jara P . High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol. 2010; 52(4):501-7. DOI: 10.1016/j.jhep.2010.01.016. View

Butler A, Williams P, Howland L, Storm D, Hutton N, Seage 3rd G . Impact of disclosure of HIV infection on health-related quality of life among children and adolescents with HIV infection. Pediatrics. 2009; 123(3):935-43. PMC: 2697844. DOI: 10.1542/peds.2008-1290. View

10.

Frange P, Briand N, Veber F, Moshous D, Avettand-Fenoel V, Rouzioux C . CCR5 antagonists: a therapeutic option in HIV-1 perinatally infected children experiencing virologic failure?. AIDS. 2012; 26(13):1673-7. DOI: 10.1097/QAD.0b013e3283553776. View

11.

Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G . British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). HIV Med. 2013; 15 Suppl 1:1-85. DOI: 10.1111/hiv.12119. View

12.

Judd A, Ferrand R, Jungmann E, Foster C, Masters J, Rice B . Vertically acquired HIV diagnosed in adolescence and early adulthood in the United Kingdom and Ireland: findings from national surveillance. HIV Med. 2009; 10(4):253-6. DOI: 10.1111/j.1468-1293.2008.00676.x. View

13.

Madhi S, Adrian P, Cotton M, McIntyre J, Jean-Philippe P, Meadows S . Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis. 2010; 202(3):355-61. PMC: 2902789. DOI: 10.1086/653704. View

14.

Sturt A, Halpern M, Sullivan B, Maldonado Y . Timing of antiretroviral therapy initiation and its impact on disease progression in perinatal human immunodeficiency virus-1 infection. Pediatr Infect Dis J. 2011; 31(1):53-60. PMC: 3252403. DOI: 10.1097/INF.0b013e31823515a2. View

15.

Schaaf H, Cotton M, Boon G, Jeena P . Isoniazid preventive therapy in HIV-infected and -uninfected children (0 - 14 years). S Afr Med J. 2013; 103(10):714-5. DOI: 10.7196/samj.7189. View

16.

Sabin C, Cooper D, Collins S, Schechter M . Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons. AIDS. 2013; 27(12):1839-46. DOI: 10.1097/qad.0b013e328360d546. View

17.

Bhowan K, Sherman G . Performance of the first fourth-generation rapid human immunodeficiency virus test in children. Pediatr Infect Dis J. 2012; 32(5):486-8. DOI: 10.1097/INF.0b013e31827b4775. View

18.

Akolo C, Adetifa I, Shepperd S, Volmink J . Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010; (1):CD000171. PMC: 7043303. DOI: 10.1002/14651858.CD000171.pub3. View

19.

Mehta U, Maartens G . Is it safe to switch between efavirenz and nevirapine in the event of toxicity?. Lancet Infect Dis. 2007; 7(11):733-8. DOI: 10.1016/S1473-3099(07)70262-1. View

20.

Ruxrungtham K, Pedro R, Latiff G, Conradie F, Domingo P, Lupo S . Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med. 2008; 9(10):883-96. DOI: 10.1111/j.1468-1293.2008.00644.x. View